StockData
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. (TRVI) stock

TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$13.35−0.37 (-2.70%)

Close on Nov 20, 2026Market cap $1.90BP/E –Yield –

Trevi Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Trevi Therapeutics

Trevi Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Trevi Therapeutics figures

See a number that looks wrong?